Zobrazeno 1 - 10
of 51
pro vyhledávání: '"J A Hank"'
Autor:
K R, Oettel, O H, Wesly, M R, Albertini, J A, Hank, O, Iliopolis, J A, Sosman, K, Voelkerding, S Q, Wu, S S, Clark, P M, Sondel
Publikováno v:
Blood. 83:3390-3402
Immunocompetent cells in bone marrow allografts have been associated with a graft-versus-leukemia (GVL) effect. To further characterize effector mechanisms that may be involved in this GVL phenomenon, we have previously established an in vitro model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::629a8f0beb90e4386df68a39ef8e81da
https://doi.org/10.1182/blood.v83.11.3390.bloodjournal83113390
https://doi.org/10.1182/blood.v83.11.3390.bloodjournal83113390
Publikováno v:
The Journal of Immunology. 145:36-45
HLA-loss variants of an EBV-transformed B lymphoblastoid cell line (EBV-LCL) 721 were used to investigate whether human MHC molecules other than known class I or class II were involved in autologous T cell responses. Bulk lymphocyte cultures of purif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12944b53e75f9d49254b794588249d1e
https://doi.org/10.4049/jimmunol.145.1.36
https://doi.org/10.4049/jimmunol.145.1.36
Publikováno v:
Cancer chemotherapy and biological response modifiers. 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a5d37ec8aef24932194891be1b044e86
https://pubmed.ncbi.nlm.nih.gov/10800484
https://pubmed.ncbi.nlm.nih.gov/10800484
Autor:
K M, Hotton, M, Khorsand, J A, Hank, M, Albertini, K M, Kim, G, Wilding, M S, Salamat, M, Larson, P, Sondel, J H, Schiller
Publikováno v:
Cancer. 88(8)
Interleukin-2 (IL-2) and granulocyte-macrophage-colony stimulating factor (GM-CSF) are cytokines with nonoverlapping pleiotropic effects. In a prior Phase Ib study, this combination of agents exhibited antitumor effects in the lungs of four of eight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e55d9f75b316ebcf64a17b46ca0babdf
https://pubmed.ncbi.nlm.nih.gov/10760767
https://pubmed.ncbi.nlm.nih.gov/10760767
Autor:
J A, Hank, J, Surfus, J, Gan, M, Albertini, M, Lindstrom, J H, Schiller, K M, Hotton, M, Khorsand, P M, Sondel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(2)
Interleukin-2 (IL-2) is a potent lymphokine that activates natural killer cells, T cells, and other cells of the immune system. Several distinct recombinant human IL-2 preparations have shown antitumor activity, particularly for renal cell cancer and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cb13c7956bbe40dd0ed86681d8127aee
https://pubmed.ncbi.nlm.nih.gov/10037176
https://pubmed.ncbi.nlm.nih.gov/10037176
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(5)
Lymphocytes from patients receiving in vivo interleukin (IL)-2 therapy possess enhanced in vitro proliferative and cytotoxic responses to IL-2. The cells from these patients that respond to exogenous IL-2 are CD56+ natural killer cells expressing int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::876a2302a546f19b4939023690457315
https://pubmed.ncbi.nlm.nih.gov/9607589
https://pubmed.ncbi.nlm.nih.gov/9607589
Autor:
P M, Sondel, J A, Hank
Publikováno v:
The cancer journal from Scientific American. 3
Administration of recombinant interleukin-2 (rIL-2) causes activation of natural killer (NK) cells, which express CD16, the Fc receptor gamma III (Fc gamma III), and can mediate antibody-dependent cellular cytotoxicity (ADCC). In an effort to generat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2a9da2d8a20bdb48b5e742f49d968f96
https://pubmed.ncbi.nlm.nih.gov/9457407
https://pubmed.ncbi.nlm.nih.gov/9457407
Autor:
M R, Albertini, J A, Hank, J H, Schiller, M, Khorsand, A A, Borchert, J, Gan, R, Bechhofer, B, Storer, R A, Reisfeld, P M, Sondel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(8)
We conducted a Phase IB trial of antidisialoganglioside chimeric 14. 18 (ch14.18) antibody and interleukin 2 (IL-2) to determine the maximal tolerated dose (MTD), immunological effects, antitumor effects, and toxicity of this treatment combination. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3d2b65fd66bfd662c57c2fa8d28441dd
https://pubmed.ncbi.nlm.nih.gov/9815810
https://pubmed.ncbi.nlm.nih.gov/9815810
Autor:
J D, Frost, J A, Hank, G H, Reaman, S, Frierdich, R C, Seeger, J, Gan, P M, Anderson, L J, Ettinger, M S, Cairo, B R, Blazar, M D, Krailo, K K, Matthay, R A, Reisfeld, P M, Sondel
Publikováno v:
Cancer. 80(2)
The murine monoclonal antibody (MoAb) 14.G2a recognizes GD2, a disialoganglioside expressed in tumors of neuroectodermal origin, and facilitates antibody dependent cellular cytotoxicity (ADCC) in vitro. When given in vivo, interleukin-2 (IL-2) can in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63b06a98920245542d2f5a8c7c875311
https://pubmed.ncbi.nlm.nih.gov/9217046
https://pubmed.ncbi.nlm.nih.gov/9217046
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(12)
Cytotoxic effector cells interact with target cells through various mechanisms. CTLs use the antigen-specific T cell receptor, whereas Fc receptor-positive natural killer cells use this receptor to interact with antibody-coated target cells. We evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eab5f5a7050e9ec3f5954f310f9c2219
https://pubmed.ncbi.nlm.nih.gov/9816154
https://pubmed.ncbi.nlm.nih.gov/9816154